We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,200.60
Bid: 1,197.40
Ask: 1,198.00
Change: 9.80 (0.82%)
Spread: 0.60 (0.05%)
Open: 1,202.60
High: 1,215.20
Low: 1,195.80
Yest. Close: 1,190.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

FTSE 100 movers: TUI Travel disappointment

Travel operator TUI Travel is the biggest faller in the Footsie after it warned profits this year will be at the low end of forecasts after poor bookings. TUI's third quarter profit of £103m was in line with expectations. Volcanic ash disruption cost £105m. Bookings by Britons are down by 2% over

10 Aug 10 13:49

MARKET TALK: Ambrian Starts Drug Maker Vectura At Buy

1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Chris Redhead says the drug maker is significantly undervalued. A program with Novartis (NOVN.VX) could bring the companies a significant share of the $9 billion-a-year market f

2 Aug 10 14:21

UK MARKET TALK ROUNDUP: BROKERS COMMENTS

Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Ch

2 Aug 10 14:21

GlaxoSmithKline Consumer 2Q Net Profit Rises 30% To INR717.5 Mln

BANGALORE (Dow Jones)--India's GlaxoSmithKline Consumer Healthcare Ltd. (500676.BY) said Monday net profit for the second quarter jumped 30% to INR717.5 million from INR551.9 million a year earlier. Sales for the quarter through June rose 15% to INR5.37 billion from INR4.69 billion, said the ass

2 Aug 10 10:36

Aurobindo Pharma Gets US OK To Sell Generic Heartburn Syrup

BANGALORE (Dow Jones)--Aurobindo Pharma Ltd. (524804.BY) Monday said it has received a final approval from the U.S Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Zantac syrup for treating heartburn. Aurobindo Pharma is ready to start selling ranitidine hydr

2 Aug 10 06:09

UPDATE: FDA Approves Vaccines for 2010-11 Flu Season

(Update in last paragraph with list of companies making the flu vaccine.) By Shayndi Raice Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The U.S. Food and Drug Administration announced Friday it has approved vaccines for the 2010-2011 flu season. The latest flu vaccine will prevent

30 Jul 10 19:57

PRESS RELEASE: GlaxoSmithKline Begins Distribution of Flu Vaccine to U.S. Customers for 2010-2011 Flu Season

PHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval(R) [Influenza Virus Vaccine] allowing distribution in the U.S. to

30 Jul 10 13:30

2nd UPDATE: Amgen 2Q Profit Drops 5.3% As Costs Rise

(Updates throughout with details, company comment.) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Amgen Inc. (AMGN) reported a 5.3% drop in second-quarter net income, as total sales of its products dropped and spending rose in preparation of a key product launch. The T

29 Jul 10 23:58

UPDATE: Amgen 2Q Profit Drops 5.3% As Cost Rise

(Updates throughout with details, background) By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Amgen Inc. (AMGN) reported a 5.3% drop in second-quarter net income, as total sales of its products dropped and spending rose in preparation of a key product launch. The Thousan

29 Jul 10 22:15

GlaxoSmithKline Gets Exclusive License For Gsk2251052 Drug

LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN) said Thursday it has exercised its option to obtain an exclusive license to develop and commercialize GSK2251052, or GSK 052, formerly known as AN3365. MAIN FACTS: -GSK '052 is a novel, systemic antibiotic derived from Anacor Pharmaceuticals'

29 Jul 10 16:18

PRESS RELEASE: Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease

CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals Inc. (Nasdaq: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious dis

29 Jul 10 12:00

OPTIONS REPORT:Genzyme Takeover Rumors Meet With Some Skepticism

By Brendan Conway Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--For one big options trader, the takeover chatter on Genzyme Corp. could be just that--chatter. The Cambridge, Mass., biotechnology company has been the subject of buyout rumors recently, with French drug maker Sanofi-Aventis

27 Jul 10 20:30

On Dow Jones Investment Banker Today: Genzyme, Kirin, Booz Allen

LONDON (Dow Jones Investment Banker)--The following columns have been published exclusively on Dow Jones Investment Banker in recent days. Many Dow Jones Investment Banker columns contain spreadsheets, video, PDFs and other supporting material. To arrange access to the best of Dow Jones news and opi

27 Jul 10 20:08

UPDATE: Merck In Talks For China Partnership >MRK

(Updates to focus on China partnership; adds new details and background; updates stock prices) By Peter Loftus Of DOW JONES NEWSWIRES Merck & Co. (MRK) said Tuesday it was in talks with China's Sinopharm Group Co. (SHTDF, 1099.HK) for a venture to market vaccines and potentially Merck

27 Jul 10 16:09

US HOT STOCKS: CBOE, Delta Pete, FMC Technologies, Genzyme -2-

CBOE Holdings Inc. (CBOE, $26.50, -$0.65, -2.39%) shares fell just over a month after the company went public as several Wall Street analysts initiated coverage of the stock; most agreed that the exchange's dominant position in options is a key asset, but said competition and light trading volume wi

26 Jul 10 22:01

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.